Two Sigma Advisers’s Oncolytics Biotech ONCY Stock Holding History

Two Sigma Advisers’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,900	Closed	-$11K	–	2683
2022 Q2	$11K	Sell	10,900 -13,200	-55%	-$16.1K	﹤0.01%	2586
2022 Q1	$38K	Sell	24,100 -18,100	-43%	-$30.4K	﹤0.01%	2616
2021 Q4	$59K	Buy	42,200 +3,000	+8%	+$5.55K	﹤0.01%	2462
2021 Q3	$82K	Sell	39,200 -51,800	-57%	-$117K	﹤0.01%	2338
2021 Q2	$252K	Sell	91,000 -1,900	-2%	-$5.82K	﹤0.01%	2197
2021 Q1	$354K	Sell	92,900 -32,400	-26%	-$96.7K	﹤0.01%	2163
2020 Q4	$298K	Buy	125,300 +3,300	+3%	+$7.91K	﹤0.01%	2049
2020 Q3	$206K	Sell	122,000 -24,100	-16%	-$44.2K	﹤0.01%	2146
2020 Q2	$275K	Sell	146,100 -4,600	-3%	-$8.66K	﹤0.01%	2155
2020 Q1	$208K	Buy	+150,700	New	+$376K	﹤0.01%	2156

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Two Sigma Advisers's ONCY Position: Q3 2022 in Review

Two Sigma Advisers sold out of Oncolytics Biotech (ONCY) in Q3 2022, closing a stake of 10,900 shares — an estimated $11K sold.

Two Sigma Advisers first reported a position in ONCY in Q1 2020 and held it in 10 quarters. The position peaked at $354K in Q1 2021. 36 funds tracked by Wall St. Rank hold ONCY as of Q3 2022.

Two Sigma Advisers reported no remaining Oncolytics Biotech position as of Q3 2022 after selling out during the quarter.
Two Sigma Advisers sold 10,900 Oncolytics Biotech shares in Q3 2022, an estimated $11K.
Two Sigma Advisers first reported a position in Oncolytics Biotech in Q1 2020 and held it in 10 quarters.
Two Sigma Advisers's Oncolytics Biotech position peaked at $354K in Q1 2021.
36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.